<p>Supplementary Figure 1. Expansion of adaptive NK cells from C1/C2 donors depends on original imprint. Supplemental Figure 2. Selective expansion of NKG2C NKG2A- NK cells depends on stimulation with HLA-E expressing feeder cells. Supplementary Figure 3. Expression of granzymes and perforin before and after in vitro expansion of adaptive NK cells. Supplementary Figure 4. Adaptive NK cells recognize MDS and AML blasts. Supplementary Figure 5. Sorting of adaptive NK cells for functional studies.</p>
Funding
Horizon 2020
National Science Center, Poland
French National Research Agency
ARTICLE ABSTRACT
Manipulation of human natural killer (NK) cell repertoires promises more effective strategies for NK cell–based cancer immunotherapy. A subset of highly differentiated NK cells, termed adaptive NK cells, expands naturally in vivo in response to human cytomegalovirus (HCMV) infection, carries unique repertoires of inhibitory killer cell immunoglobulin-like receptors (KIR), and displays strong cytotoxicity against tumor cells. Here, we established a robust and scalable protocol for ex vivo generation and expansion of adaptive NK cells for cell therapy against pediatric acute lymphoblastic leukemia (ALL). Culture of polyclonal NK cells together with feeder cells expressing HLA-E, the ligand for the activating NKG2C receptor, led to selective expansion of adaptive NK cells with enhanced alloreactivity against HLA-mismatched targets. The ex vivo expanded adaptive NK cells gradually obtained a more differentiated phenotype and were specific and highly efficient killers of allogeneic pediatric T- and precursor B-cell acute lymphoblastic leukemia (ALL) blasts, previously shown to be refractory to killing by autologous NK cells and the NK-cell line NK92 currently in clinical testing. Selective expansion of NK cells that express one single inhibitory KIR for self-HLA class I would allow exploitation of the full potential of NK-cell alloreactivity in cancer immunotherapy. In summary, our data suggest that adaptive NK cells may hold utility for therapy of refractory ALL, either as a bridge to transplant or for patients that lack stem cell donors. Cancer Immunol Res; 5(8); 654–65. ©2017 AACR.
